Chiome Bioscience Management
Management criteria checks 2/4
Chiome Bioscience's CEO is Masamichi Koike, appointed in Jan 2025, has a tenure of 1.67 years. directly owns 0.045% of the company’s shares, worth ¥3.07M. The average tenure of the management team and the board of directors is 6.3 years and 3.5 years respectively.
Key information
Masamichi Koike
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.05% |
| Management average tenure | 6.3yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
CEO
Masamichi Koike (64 yo)
Dr. Masamichi Koike, PhD wad the Head of Research Function of R&D Division and Fellow at Kyowa Kirin Co. Ltd. He serves as Executive Director at Chiome Bioscience Inc. since March 2023 and serves as its Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.7yrs | no data | 0.045% ¥ 3.1m | |
| Executive VP | 9.4yrs | no data | 0.094% ¥ 6.3m | |
| Head of Development Division & Director | 6.3yrs | no data | 0.058% ¥ 3.9m |
Experienced Management: 4583's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | no data | 0.045% ¥ 3.1m | |
| Executive VP | 9.4yrs | no data | 0.094% ¥ 6.3m | |
| Head of Development Division & Director | 3.5yrs | no data | 0.058% ¥ 3.9m | |
| Independent Outside Director | 6.5yrs | no data | no data | |
| Independent Outside Director | 1.5yrs | no data | 0.016% ¥ 1.1m | |
| Independent Outside Director | 1.5yrs | no data | no data | |
| Independent Outside Director | 5.5yrs | no data | no data |
Experienced Board: 4583's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 18:59 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chiome Bioscience Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akitada Iwasa | Daiwa Securities Co. Ltd. |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |